Solid Biosciences Inc. (SLDB)
Company Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States.
The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy.
It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids.
The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy.
Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Jan 26, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Alexander G. Cumbo |
Contact Details
Address: 141 Portland Street Cambridge, Massachusetts United States | |
| Website | https://www.solidbio.com |
Stock Details
| Ticker Symbol | SLDB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001707502 |
| CUSIP Number | 83422E105 |
| ISIN Number | US83422E2046 |
| Employer ID | 90-0943402 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Alexander G. Cumbo | President, Chief Executive Officer & Director |
| David Tyronne Howton Jr., J.D. | Chief Operating Officer & Secretary |
| Allison Bogosian J.D. | Senior Vice President of Human Resources |
| Annie Ganot | Co-Founder & Vice President of Patient Advocacy |
| Dr. Shuli Kulak M.D. | Head of Corporate Strategy & Business Development |
| Ian F. Smith A.C.A., C.P.A. | Executive Chair |
| Nicole Anderson | Director of Investor Relations & Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 17, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 11, 2025 | PRE 14A | Filing |
| Apr 08, 2025 | 4 | Filing |
| Mar 13, 2025 | 4 | Filing |
| Mar 06, 2025 | S-3 | Filing |
| Mar 06, 2025 | S-3 | Filing |
| Mar 06, 2025 | S-8 | Filing |